Biophytis Deploys Its Partnership Strategy and Signs Two Contracts With Local Agents in Asia
Biophytis Deploys Its Partnership Strategy and Signs Two Contracts With Local Agents in Asia
Japan and China are two strategic markets for Biophytis. Indeed, Japan has the largest population in the world suffering from sarcopenia, with more than 1 in 5 people aged 60 and over affected (source: Yuan 2023, Epidemiology of Sarcopenia, Metabolism). Additionally, more than 70 million Chinese adults are affected by obesity, making it the second-largest population worldwide with this pathology (source: ).PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 22, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, today announces the deployment of its partnership strategy in Asia.
2024年7月22日，位于法国巴黎和马萨诸塞州剑桥市的生物医药公司Biophytis SA（Euronext Growth Paris：ALBPS）（“Biophytis”或“公司”），宣布在亚洲部署合作伙伴策略。该公司是一家专注于开发面向衰老疾病治疗的临床阶段生物技术公司。
To expand its presence in this strategic region, Biophytis has today signed two contracts with local agents: one for Japan and South Korea, the other for China and Southeast Asia. These agents will leverage their networks within the pharmaceutical sector to support Biophytis in identifying partners for the drug candidate BIO101 (20-hydroxyecdysone) in these different countries.
为了扩大在这一关键地区的影响力，Biophytis已经与当地代理商签订了两份合同：一份涉及日本和韩国，另一份涉及中国和东南亚。这些代理商将利用其在药品领域内的网络，支持Biophytis在这些不同的国家寻找候选药物BIO101（20-羟基蜕皮酮）的合作伙伴。
This initiative is part of the partnership development strategy in Asia, aimed at accelerating the deployment of BIO101 in this key geography, the second largest pharmaceutical market in the world. Biophytis is determined to establish successful collaborations to meet patients' needs and make significant advances in the various targeted pathologies.
这一举措是该公司在亚洲推行合作伙伴发展策略的一部分，旨在加速在全球第二大药品市场的关键地理位置部署BIO101。Biophytis决心建立成功的合作关系，以满足患者需求，并在各种有针对性的病理状况方面取得重要进展。
Japan and China are two strategic markets for Biophytis. Indeed, Japan has the largest population in the world suffering from sarcopenia, with more than 1 in 5 people aged 60 and over affected (source: Yuan 2023, Epidemiology of Sarcopenia, Metabolism). Additionally, more than 70 million Chinese adults are affected by obesity, making it the second-largest population worldwide with this pathology (source: ).
日本和中国是Biophytis的两个战略市场。实际上，日本拥有全球最多患有肌无力症的人口，超过五分之一的60岁及以上人群受影响（来源：Yuan 2023年《肌无力症流行病学》）。此外，有超过7000万中国成年人患有肥胖症，成为全球第二大的这种病理人口（来源：).
Following the exclusive license agreement signed with Blanver, one of the leading pharmaceutical companies in Brazil, for BIO101 (20-Hydroxyecdysone) in Latin America, Biophytis aims to sign new co-development and commercialization agreements with industrial partners in Asia and also in North America, the world's largest pharmaceutical market.
在与巴西领先制药公司Blanver签署BIO101（20-羟基蜕皮酮）在拉丁美洲的独家许可协议后，Biophytis旨在与亚洲和北美的工业合作伙伴签署新的共同开发和商业化协议，这是全球最大的药品市场。
****
****
About BIOPHYTIS
关于Biophytis
Biophytis SA is a clinical-stage biotechnology company specializing in the development of drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular (sarcopenia, phase 3 ready and Duchenne muscular dystrophy, phase 1-2 study to be started, respiratory (Covid-19, phase 2 completed) and metabolic diseases (obesity, phase 2 to be started). The company is based in Paris, France, and Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825). For more information, visit
Biophytis SA是一家临床生物技术公司，专注于开发面向年龄相关疾病的候选药物。BIO101（20-羟基蜕皮激素）是我们的主导药物候选药物，是一种小分子药物，用于肌肉（肌肉萎缩，第3期待启动和杜兴肌肉萎缩，第1-2期即将启动）、呼吸（COVID-19，第2期已完成）和代谢性疾病（肥胖症，第2期将启动）的研究。该公司总部位于法国巴黎和美国马萨诸塞州的剑桥。公司普通股在Euronext Growth上市（Ticket：ALBPS - ISIN: FR0012816825）。了解更多信息，请访问
Forward-looking statements
前瞻性声明 本新闻稿中包括的关于未来表现和结果、预期、规划、策略、重点、承诺和其他声明（包括与我们社会、环境和其他可持续性目标有关的声明）的非历史事实的前瞻性声明，是根据美国联邦证券法的定义而作出的前瞻性声明。本新闻稿中关于我们环境和其他可持续性计划和目标的前瞻性声明以及其他声明并不意味着这些声明对于投资者、我们的业务、运营结果、财务状况、前景或策略、对我们在可持续发展事项上的影响或其他当事方来说均是重要的，或者必须披露在我们向证券交易委员会（“SEC”）或其他监管机构的备案中。此外，历史、现有及未来涉及社会、环境和可持续性的相关声明可能是基于仍在发展的衡量进展的标准、不断演变的内部控制和流程以及假设，在将来可能会发生变化。前瞻性声明基于当前的信仰、期望和假设，并受到可能导致实际结果与前瞻性声明有实质性差异的重大风险、不确定性和情况变化的影响。
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face» section from the Company's 2023 Financial Report available on BIOPHYTIS website () and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.
本新闻稿包含前瞻性声明。前瞻性声明包括所有非历史事实陈述。 在某些情况下，您可以通过使用“前景展望”，“相信”，“期望”，“潜力”，“继续，”，“可能”，“将” ，“应该”，“可能”，“寻求”，“预测”，“打算”，“趋势”，“计划”，“估计”，“预计” 或这些词的负面版本或其他可比较的词语来识别这些前瞻性陈述。 这类前瞻性声明是基于Biophytis认为合理的假设。然而，不能保证这些前瞻性陈述中包含的陈述将得到证实，这些陈述还可能受到各种风险和不确定性的影响。此 新闻稿中包含的前瞻性声明也可能受到 Biophytis 尚未了解或目前不认为重要的风险的影响。因此，存在或将存在重要因素可能导致实际结果或成果与这些声明中指示的结果存在重大差异。此外，请参阅 Biophytis 网站上可用的2023年财务报告中的“公司即将面临的风险与不确定性”部分以及20-F表格中的“风险因素”部分以及提交给美国证券交易委员会（SEC）的其他表格。我们没有义务公开更新或审查任何前瞻性声明，无论是因为新的信息，未来的发展还是其他情况，除非法律要求。
Contacts Biophytis
Biophytis联系方式
Investor relations
Nicolas Fellmann, CFO
Investors@biophytis.com
投资者关系
Nicolas Fellmann，CFO
Investors@biophytis.com
Media
媒体
Antoine Denry: antoine.denry@taddeo.fr - +33 6 18 07 83 27
Nizar Berrada: nizar.berrada@taddeo.fr - +33 6 38 31 90 50
安托万·登里：antoine.denry@taddeo.fr - +33 6 18 07 83 27
尼泽尔·贝拉达：nizar.berrada@taddeo.fr - +33 6 38 31 90 50
SOURCE: Biophytis
来源：Biophytis
